Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.48 |
| ▸ | RAF1 | P04049 | 5/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114705 | 0.79 | PDE4A (0.35) | DYRK1ARAF1 | |
| SCHEMBL3121332 | 0.78 | MAP4K4 (0.41) | DYRK1AMAPK14PDGFRBPDGFRACLK2 | |
| SCHEMBL18544272 | 0.76 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL14126236 | 0.76 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL14905509 | 0.75 | DYRK1A (0.44) | DYRK1ARAF1PDGFRBPDGFRACYP19A1 | |
| SCHEMBL4502318 | 0.75 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL3379185 | 0.75 | MAP4K4 (0.41) | MAPK1KCNH2 | |
| SCHEMBL3618066 | 0.75 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL29692876 | 0.75 | ERN1 (0.44) | PDGFRBPDGFRARPS6KA3KCNH2 | |
| SCHEMBL2490082 | 0.75 | ERN1 (0.44) | PDGFRBPDGFRARPS6KA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2154965-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | INPP5D, PI4KA, PTEN | DYRK1A 2236/4885RAF1 953/4885MAPK14 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.